Reproducible Molecular Subtypes in Systemic Lupus Erythematosus Are Associated With Disease Activity, Serology, and Distinct Trajectories Over Time - Report - MDSpire
Clinical Report: Consistent Molecular Subtypes in Systemic Lupus Erythematosus
Overview
This study identifies robust molecular subtypes in systemic lupus erythematosus (SLE) using three large cohorts, revealing correlations with disease activity and serological profiles.
Background
Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by diverse manifestations that complicate diagnosis and treatment. Molecular stratification approaches are essential for improving patient subtyping and developing targeted therapies.
Data Highlights
No numerical data or trial data provided in the source material.
Key Findings
Three large SLE cohorts were utilized to identify molecular subtypes.
Molecular subtypes correlated with disease activity and serological profiles.
IFN signatures were linked to renal involvement in SLE patients.
B cell/plasmablast activation was associated with serologic activity.
Longitudinal stability and clinical improvement were evaluated in the LOTUS cohort.
Clinical Implications
Clinicians should consider molecular profiles when assessing disease activity and treatment responses.
Conclusion
Further research is necessary to validate these findings across diverse patient populations.
Creatine's ATP-buffering trick isn't just for biceps. In mice, it juices up dendritic cells' energy supply, sharpening T-cell priming and shrinking tumors on daily injections. Human DCs got the memo too, at least in a dish. Early days, but a fun plot twist for gym-bag chemistry.
